Needham Maintains Buy on Viridian Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a Buy rating on Viridian Therapeutics (NASDAQ:VRDN) and kept the price target at $30.
March 20, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger reaffirms a Buy rating on Viridian Therapeutics with a $30 price target.
The maintenance of a Buy rating and a $30 price target by a reputable analyst like Serge Belanger suggests a positive outlook on VRDN's stock. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100